MCID: PHY001
MIFTS: 28

Physiological Polycythemia malady

Categories: Blood diseases

Aliases & Classifications for Physiological Polycythemia

Aliases & Descriptions for Physiological Polycythemia:

Name: Physiological Polycythemia 12 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:8431
NCIt 47 C27311
UMLS 69 C0856817

Summaries for Physiological Polycythemia

MalaCards based summary : Physiological Polycythemia is related to intussusception and tau syndrome. An important gene associated with Physiological Polycythemia is IL1B (Interleukin 1 Beta), and among its related pathways/superpathways are NF-kappaB Signaling and T cell receptor signaling pathway. The drugs Acetazolamide and Epinephrine have been mentioned in the context of this disorder.

Related Diseases for Physiological Polycythemia

Diseases related to Physiological Polycythemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 132)
id Related Disease Score Top Affiliating Genes
1 intussusception 10.1 IL1B TNF
2 tau syndrome 10.1 IL1B TNF
3 stocco dos santos syndrome 10.1 IL1B TNF
4 hypotrichosis-lymphedema-telangiectasia-renal defect syndrome 10.0 IL1B TNF
5 twin-to-twin transfusion syndrome 10.0 IL1B TNF
6 warthin tumor 10.0 IL1B TNF
7 anal paget's disease 10.0 IL1B TNF
8 cataract 10.0 IL1B TNF
9 hepatic encephalopathy 10.0 IL1B TNF
10 bipolar i disorder 10.0 IL1B TNF
11 human immunodeficiency virus infectious disease 10.0 IL1B TNF
12 cerebellar disease 10.0 IL1B TNF
13 tinea capitis 10.0 IL1B TNF
14 amyotrophic lateral sclerosis type 14 10.0 IL1B TNF
15 measles 10.0 IL1B TNF
16 parkinson disease 11 10.0 IL1B TNF
17 dextrocardia 10.0 IL1B TNF
18 meier-gorlin syndrome 3 10.0 IL1B TNF
19 hypoparathyroidism-retardation-dysmorphism syndrome 10.0 IL1B TNF
20 gastroduodenal crohn's disease 10.0 IL1B TNF
21 childhood endodermal sinus tumor 10.0 IL1B TNF
22 steroid dehydrogenase deficiency dental anomalies 10.0 IL1B TNF
23 mikulicz disease 10.0 IL1B TNF
24 senile reticular retinal degeneration 10.0 IL1B TNF
25 acquired thrombocytopenia 10.0 IL1B TNF
26 benign neonatal seizures 10.0 IL1B TNF
27 rheumatoid factor-negative juvenile idiopathic arthritis without anti-nuclear antibodies 10.0 IL1B TNF
28 gonococcal endophthalmia 10.0 IL1B TNF
29 ectodermal dysplasia bartalos type 10.0 IL1B TNF
30 pyloric stenosis, infantile hypertrophic, 2 10.0 IL1B TNF
31 mineral metabolism disease 10.0 IL1B TNF
32 migraine with aura 10.0 IL1B TNF
33 rickettsialpox 10.0 IL1B TNF
34 autosomal recessive type iv ehlers-danlos syndrome 10.0 IL1B TNF
35 bladder signet ring cell adenocarcinoma 10.0 IL1B TNF
36 neuropathy 10.0 IL1B TNF
37 keratoconus 10.0 IL1B TNF
38 motility-related diarrhea 10.0 IL1B TNF
39 splenic artery aneurysm 10.0 IL1B TNF
40 urticaria 10.0 IL1B TNF
41 wound botulism 10.0 IL1B TNF
42 inappropriate adh syndrome 10.0 IL1B TNF
43 ovarian cystic teratoma 10.0 IL1B TNF
44 patau syndrome 10.0 IL1B TNF
45 central nervous system lymphoma 10.0 IL1B TNF
46 tuberculosis 10.0 IL1B TNF
47 nasal cavity cancer 10.0 IL1B TNF
48 labyrinthitis 10.0 IL1B TNF
49 pancreas lymphoma 10.0 IL1B TNF
50 atrophy of prostate 10.0 IL1B TNF

Graphical network of the top 20 diseases related to Physiological Polycythemia:



Diseases related to Physiological Polycythemia

Symptoms & Phenotypes for Physiological Polycythemia

Drugs & Therapeutics for Physiological Polycythemia

Drugs for Physiological Polycythemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 244)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetazolamide Approved, Vet_approved Phase 4,Phase 1,Phase 2 59-66-5 1986
2
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
3
Zinc Approved Phase 4 7440-66-6 32051 23994
4 Anticonvulsants Phase 4,Phase 1,Phase 2
5 Carbonic Anhydrase Inhibitors Phase 4,Phase 1,Phase 2
6 diuretics Phase 4,Phase 1,Phase 2
7 Natriuretic Agents Phase 4,Phase 1,Phase 2
8 Epinephryl borate Phase 4
9 Hypoglycemic Agents Phase 4,Phase 2,Phase 3
10 insulin Phase 4
11 Insulin, Globin Zinc Phase 4
12 Racepinephrine Phase 4
13
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
14
Busulfan Approved, Investigational Phase 2, Phase 3,Phase 1 55-98-1 2478
15
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 498142 38904
16
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1 50-18-0, 6055-19-2 2907
17
Fludarabine Approved Phase 2, Phase 3, Phase 1 21679-14-1, 75607-67-9 30751
18
Peginterferon alfa-2b Approved Phase 3,Phase 1,Phase 2 99210-65-8, 215647-85-1
19
Hydroxyurea Approved Phase 3,Phase 2 127-07-1 3657
20
Metformin Approved Phase 2, Phase 3 657-24-9 14219 4091
21
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
22
Ondansetron Approved Phase 3,Phase 1,Phase 2 99614-02-5 4595
23
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
24
Guaifenesin Approved, Vet_approved Phase 3 93-14-1 3516
25
Morphine Approved, Investigational Phase 3 57-27-2 5288826
26
Lenalidomide Approved Phase 3,Phase 2 191732-72-6 216326
27 Pomalidomide Approved Phase 3,Phase 1,Phase 2 19171-19-8
28
Aspirin Approved, Vet_approved Phase 3,Phase 2 50-78-2 2244
29
Peginterferon alfa-2a Approved, Investigational Phase 3,Phase 2,Phase 1 198153-51-4 5360545
30
Etoposide Approved Phase 2, Phase 3,Phase 1 33419-42-0 36462
31
Melphalan Approved Phase 2, Phase 3,Phase 1 148-82-3 4053 460612
32
Thiotepa Approved Phase 2, Phase 3,Phase 1 52-24-4 5453
33
Anagrelide Approved Phase 3 68475-42-3 2182
34
Methyltestosterone Approved Phase 3 58-18-4 6010
35
Testosterone Approved, Investigational Phase 3 58-22-0 6013
36 Analgesics Phase 3,Phase 2,Phase 1
37 Anesthetics Phase 3
38 Anesthetics, Dissociative Phase 3
39 Anesthetics, General Phase 3
40 Anesthetics, Intravenous Phase 3
41 Central Nervous System Depressants Phase 3,Phase 1,Phase 2
42 Excitatory Amino Acid Antagonists Phase 3
43 Excitatory Amino Acids Phase 3
44 Neurotransmitter Agents Phase 3,Phase 2
45 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
46 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1
47 Dermatologic Agents Phase 3,Phase 2,Phase 1
48 Antirheumatic Agents Phase 3,Phase 2,Phase 1
49 Anti-Bacterial Agents Phase 3,Phase 1,Phase 2
50 Immunosuppressive Agents Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 100)
id Name Status NCT ID Phase
1 Treatment of High Altitude Polycythemia by Acetazolamide Completed NCT00424970 Phase 4
2 Investigating the Accuracy of the Home Glucose Monitors in Hypoglycemia Completed NCT01013402 Phase 4
3 Glyburide Compared to Insulin in the Management of White's Classification A2 Gestational Diabetes Withdrawn NCT00160485 Phase 4
4 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3
5 Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients Completed NCT02523638 Phase 3
6 Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera Completed NCT01949805 Phase 3
7 Metformin in Obese Non-diabetic Pregnant Women Completed NCT01273584 Phase 2, Phase 3
8 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
9 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
10 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3
11 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3
12 AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study. Active, not recruiting NCT02218047 Phase 3
13 Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial) Active, not recruiting NCT01243944 Phase 3
14 Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Active, not recruiting NCT01259856 Phase 3
15 A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms Active, not recruiting NCT01387763 Phase 3
16 Phase-3 Double-Blind, Placebo-Controlled Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence Myelofibrosis and RBC-Transfusion-Dependence Active, not recruiting NCT01178281 Phase 3
17 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3
18 H-36731: Finasteride in Management of Elevated Red Blood Cells Withdrawn NCT02548117 Phase 3
19 Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera Completed NCT00241241 Phase 2
20 Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera Completed NCT01243073 Phase 2
21 Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Completed NCT01259817 Phase 2
22 CC-4047 in Treating Patients With Myelofibrosis Completed NCT00669578 Phase 1, Phase 2
23 Lenalidomide and Prednisone in Treating Patients With Myelofibrosis Completed NCT00227591 Phase 2
24 Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation Completed NCT02311569 Phase 2
25 Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Myelofibrosis Completed NCT00006367 Phase 2
26 Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid Metaplasia Completed NCT00445900 Phase 2
27 Study of Cobalt's Role in Excessive Erythrocytosis Among High Altitude Dwellers in Cerro de Pasco, Peru Completed NCT01187108 Phase 1, Phase 2
28 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia Completed NCT00381550 Phase 2
29 Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation Completed NCT00052520 Phase 1, Phase 2
30 Combination Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloproliferative Disorders Completed NCT00002792 Phase 2
31 Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder Completed NCT00054340 Phase 1, Phase 2
32 Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Myeloproliferative Disorder Completed NCT00049634 Phase 1, Phase 2
33 Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer Completed NCT00134004 Phase 2
34 Non-Ablative Allo HSCT For Hematologic Malignancies or SAA Completed NCT00006379 Phase 2
35 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00005804 Phase 2
36 Bone Marrow Transplant in Treating Patients With Hematologic Cancers Completed NCT00005797 Phase 2
37 Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders Completed NCT00005622 Phase 2
38 Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia Completed NCT00003619 Phase 1, Phase 2
39 Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer Completed NCT00002504 Phase 2
40 Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00245037 Phase 1, Phase 2
41 Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms Completed NCT02084563 Phase 2
42 A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia Completed NCT00463385 Phase 2
43 T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT00683046 Phase 2
44 Study of Nivolumab in Patients With Myelofibrosis Recruiting NCT02421354 Phase 2
45 The Benefit/Risk Profile of AOP2014 in Low-risk Patients With PV Recruiting NCT03003325 Phase 2
46 Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPeg Recruiting NCT02742324 Phase 1, Phase 2
47 Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies Recruiting NCT02556931 Phase 2
48 Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies Recruiting NCT01760655 Phase 2
49 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Recruiting NCT01384513 Phase 2
50 Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera Active, not recruiting NCT01193699 Phase 1, Phase 2

Search NIH Clinical Center for Physiological Polycythemia

Genetic Tests for Physiological Polycythemia

Anatomical Context for Physiological Polycythemia

Publications for Physiological Polycythemia

Variations for Physiological Polycythemia

Expression for Physiological Polycythemia

Search GEO for disease gene expression data for Physiological Polycythemia.

Pathways for Physiological Polycythemia

Pathways related to Physiological Polycythemia according to GeneCards Suite gene sharing:

(show all 41)
id Super pathways Score Top Affiliating Genes
1 12.18 IL1B TNF
2
Show member pathways
12.09 IL1B TNF
3
Show member pathways
12.01 IL1B TNF
4
Show member pathways
12.01 IL1B TNF
5
Show member pathways
11.96 IL1B TNF
6
Show member pathways
11.94 IL1B TNF
7 11.92 IL1B TNF
8
Show member pathways
11.88 IL1B TNF
9 11.87 IL1B TNF
10
Show member pathways
11.86 IL1B TNF
11 11.79 IL1B TNF
12 11.75 IL1B TNF
13 11.72 IL1B TNF
14 11.69 IL1B TNF
15 11.66 IL1B TNF
16
Show member pathways
11.65 IL1B TNF
17 11.61 IL1B TNF
18 11.6 IL1B TNF
19 11.59 IL1B TNF
20 11.58 IL1B TNF
21 11.55 IL1B TNF
22 11.49 IL1B TNF
23 11.46 IL1B TNF
24 11.45 IL1B TNF
25 11.36 IL1B TNF
26
Show member pathways
11.35 IL1B TNF
27 11.28 IL1B TNF
28 11.21 IL1B TNF
29 11.2 IL1B TNF
30 11.18 IL1B TNF
31 11.16 IL1B TNF
32 11.11 IL1B TNF
33
Show member pathways
11.07 IL1B TNF
34 10.95 IL1B TNF
35 10.91 IL1B TNF
36 10.9 IL1B TNF
37 10.83 IL1B TNF
38 10.75 IL1B TNF
39 10.63 IL1B TNF
40 10.3 IL1B TNF
41 9.83 IL1B TNF

GO Terms for Physiological Polycythemia

Biological processes related to Physiological Polycythemia according to GeneCards Suite gene sharing:

(show all 28)
id Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 9.64 IL1B TNF
2 leukocyte migration GO:0050900 9.63 IL1B TNF
3 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.63 IL1B TNF
4 positive regulation of protein phosphorylation GO:0001934 9.62 IL1B TNF
5 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.62 IL1B TNF
6 activation of MAPK activity GO:0000187 9.61 IL1B TNF
7 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051091 9.61 IL1B TNF
8 cellular response to organic cyclic compound GO:0071407 9.6 IL1B TNF
9 regulation of insulin secretion GO:0050796 9.59 IL1B TNF
10 positive regulation of JNK cascade GO:0046330 9.58 IL1B TNF
11 positive regulation of interferon-gamma production GO:0032729 9.58 IL1B TNF
12 positive regulation of interleukin-6 production GO:0032755 9.57 IL1B TNF
13 positive regulation of nitric oxide biosynthetic process GO:0045429 9.56 IL1B TNF
14 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.55 IL1B TNF
15 protein kinase B signaling GO:0043491 9.54 IL1B TNF
16 lipopolysaccharide-mediated signaling pathway GO:0031663 9.52 IL1B TNF
17 positive regulation of phagocytosis GO:0050766 9.51 IL1B TNF
18 positive regulation of interleukin-8 production GO:0032757 9.49 IL1B TNF
19 positive regulation of NF-kappaB import into nucleus GO:0042346 9.48 IL1B TNF
20 negative regulation of lipid catabolic process GO:0050995 9.46 IL1B TNF
21 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.43 IL1B TNF
22 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.4 IL1B TNF
23 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.37 IL1B TNF
24 positive regulation of chemokine biosynthetic process GO:0045080 9.32 IL1B TNF
25 regulation of establishment of endothelial barrier GO:1903140 9.26 IL1B TNF
26 positive regulation of fever generation GO:0031622 9.16 IL1B TNF
27 sequestering of triglyceride GO:0030730 8.96 IL1B TNF
28 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 8.62 IL1B TNF

Molecular functions related to Physiological Polycythemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.62 IL1B TNF

Sources for Physiological Polycythemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....